These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 23756600)

  • 1. Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.
    Braak H; Zetterberg H; Del Tredici K; Blennow K
    Acta Neuropathol; 2013 Nov; 126(5):631-41. PubMed ID: 23756600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alzheimer's disease. The density of amygdalar neuritic plaques is associated with the severity of neurofibrillary pathology and the degree of beta-amyloid protein deposition in the cerebral cortex.
    Yilmazer-Hanke DM
    Acta Anat (Basel); 1998; 162(1):46-55. PubMed ID: 9789108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined analysis of CSF betaA42 peptide and tau protein and serum antibodies to glycosaminoglycans in Alzheimer's disease: preliminary data.
    Briani C; Ruggero S; Naccarato M; Cagnin A; Ricchieri GL; Pasqui L; Pizzolato G; Battistin L
    J Neural Transm (Vienna); 2002 Mar; 109(3):393-8. PubMed ID: 11956959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
    Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
    Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
    Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
    Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.
    Musiek ES; Holtzman DM
    Curr Opin Neurol; 2012 Dec; 25(6):715-20. PubMed ID: 23041958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurofibrillary Tangles of Aβx-40 in Alzheimer's Disease Brains.
    Lacosta AM; Insua D; Badi H; Pesini P; Sarasa M
    J Alzheimers Dis; 2017; 58(3):661-667. PubMed ID: 28453491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical stages of amyloid-β peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease.
    Rijal Upadhaya A; Kosterin I; Kumar S; von Arnim CA; Yamaguchi H; Fändrich M; Walter J; Thal DR
    Brain; 2014 Mar; 137(Pt 3):887-903. PubMed ID: 24519982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Active caspase-6 and caspase-6-cleaved tau in neuropil threads, neuritic plaques, and neurofibrillary tangles of Alzheimer's disease.
    Guo H; Albrecht S; Bourdeau M; Petzke T; Bergeron C; LeBlanc AC
    Am J Pathol; 2004 Aug; 165(2):523-31. PubMed ID: 15277226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predisposition to accelerated Alzheimer-related changes in the brains of human immunodeficiency virus negative opiate abusers.
    Anthony IC; Norrby KE; Dingwall T; Carnie FW; Millar T; Arango JC; Robertson R; Bell JE
    Brain; 2010 Dec; 133(Pt 12):3685-98. PubMed ID: 21126996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein E is present in hippocampal neurons without neurofibrillary tangles in Alzheimer's disease and in age-matched controls.
    Han SH; Hulette C; Saunders AM; Einstein G; Pericak-Vance M; Strittmatter WJ; Roses AD; Schmechel DE
    Exp Neurol; 1994 Jul; 128(1):13-26. PubMed ID: 8070517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progression of Alzheimer-related neuritic plaque pathology in the entorhinal region, perirhinal cortex and hippocampal formation.
    Yilmazer-Hanke DM; Hanke J
    Dement Geriatr Cogn Disord; 1999; 10(2):70-6. PubMed ID: 10026378
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Amyloid-beta, tau, and dementia.
    Takashima A
    J Alzheimers Dis; 2009; 17(4):729-36. PubMed ID: 19542626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice.
    Oddo S; Caccamo A; Cheng D; Jouleh B; Torp R; LaFerla FM
    J Neurochem; 2007 Aug; 102(4):1053-63. PubMed ID: 17472708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alzheimer's disease: lesions and their progression].
    Duyckaerts C; Colle MA; Delatour B; Hauw JJ
    Rev Neurol (Paris); 1999; 155 Suppl 4():S17-27. PubMed ID: 10637934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The lesions of Alzheimer's disease: which therapeutic perspectives?].
    Duyckaerts C; Perruchini C; Lebouvier T; Potier MC
    Bull Acad Natl Med; 2008 Feb; 192(2):303-18; discussion 318-21. PubMed ID: 18819685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced Tau Aggregation in the Presence of Amyloid β.
    Bennett RE; DeVos SL; Dujardin S; Corjuc B; Gor R; Gonzalez J; Roe AD; Frosch MP; Pitstick R; Carlson GA; Hyman BT
    Am J Pathol; 2017 Jul; 187(7):1601-1612. PubMed ID: 28500862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Where, when, and in what form does sporadic Alzheimer's disease begin?
    Braak H; Del Tredici K
    Curr Opin Neurol; 2012 Dec; 25(6):708-14. PubMed ID: 23160422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of biochemical Alzheimer's disease biomarkers as end points in clinical trials.
    Siemers E; DeMattos RB; May PC; Dean RA
    Biomark Med; 2010 Feb; 4(1):81-9. PubMed ID: 20387304
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.